Charity r•gistration numb•r 1137689 (England and Wal•$l CharSty reglstrntlon number SC049777 (Scotlandl Company registration number 07272699 PANCREATIC CANCER ACTION ANNUAL REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024
PANCREATIC CANCER ACTION LEGAL AND ADMINISTRATIVE INFORMATION Trusts•s N Menezes R Legg C Carter E Cowan N Longworth L Nylander G Codaco Pisanelli (Appointed 18 March 20241 D Slatef (Appointed 18 Maich 20241 G Lesca (Appointed 18 March 20241 T Matthews (Appointed 20 August 20241 Secrotary T Matthews Charlty number (England and Wal) 1137689 Ch•rlty numb•r IS¢otlondl SC049777 Company numb•r 07272699 Reg18t•red offlc• 3 London Square Cross Lan¢$ Guildford GU1 1UJ Audltor liotts LLP 3 London Squa Cross Lanes Guildlord GU1 1UJ Corre$ponden¢e addrg8ty Surte 3.10 CoV8ult Fullarton Road Cambu$lang Glasgow G32 8YL
PANCREATIC CANCER ACTION CONTENTS Pagè CEO'S report Trustees. report 3-10 Statement of Trustees. responsibiltrs Indep&nd8nl 8udilorf$ roport 12-15 Slalemenl ol finan¢ial a¢tiviti&$ Balance sheet 17 Statement ol cash flows 18 Notes to the financial Statements 19-31
PANCREATIC CANCER ACTION CEO'S REPORT FOR THE YEAR ENDED 31 DECEMBER 2024 DELIVERING REAL RESULTS NOW; BUILDING FOR GREATER SUCCESSES IN THE FUTURE Our 2024 Annual Report highlight5 details of the real and tangible results Pancreatic Cancel Action has achieved over the past year. l am confident that readers wll be inspired by the immense activity, creativity and sheer determination ol All of the stakeholders of PCA who made Ihese successes possible. Here is a snapshot of the content ol this report.. Aworgng9$'. Working with profes5K)nal companies. a nelwork of ph8nnacy practices 8nd co81ilion5 of charities. PCA drove awareness ol pancreatic cancer symptoms across the UK. Amongst this work was a national creative digital and community outreach campaign entitled #MISSEDmoments, which reached hundreds of thousands of people to raise awareness of how missing earfy symptoms can be devastating. We are grateful lo Free P&rtners. the creative company who donated large valuable creative time and experbse. as well as all our other awareness raising partners. Advoeaey." PCA made its voicè hèard as 8 kèy partner in the SCOT-HPB pathway improvement project advocating lor clearer, faster referral pathways to save lives. Working In partnership wrth MPS, MSPS and counols we pursued the common goal ol improving diagnosis and care. Educatlon.. 2024 saw a rn8Jor drive lo prorM)le greater familiarity of symplorns and referral palhw8y8 amongst GP8 and Pharmacists with our re¥ised and &nhan¢&d eLeaming module$. Working in partnership with the NHS learning hub, Royal Phamia¢euli¢al Society, BOPA and ELE leaming, PCA 1$ well po$itioned to rea¢h every GP and most Pharmaclsts in the UK to help th8m efficientty diagnosè pancreth symptoms amon9St the general populatlon. Research.. Resear¢* is Ihe key to finding more effective methods of diagnosing paneat1¢ cancer èarfy. We have outlined our continued p8rtner3hip with the Vniversity ol Surrey on how 8 diabetes-p8ncre8tic caneer link supported the dtrvelopmenl of a algorithm now being piloted across England. pfepared the relaun¢h of our Early Dla9nosis Challenge Award lo drive eaty diagnosis. Support: People wilh PanCatIC Cancer, and their families are at the heart of PCA. In 2024 we continued to fund a Clinical Nurse Sperialisl in Glasgow. supporting over 2.500 patient interaction5 annualty. We added to our highly popular 8ccrediled health informalion booklets and digi181 resources vnth 8 new guide on genetics and pan¢reati¢ ¢8n¢gr. Fundralslng.. Fundraising is an area where it can be dea seen how a whok range of companies, trusts and foundations. communities. families and individuals took PCA to Iheir hearts. In 2024 they ran for PCA and took on challenge5. including the London Marathon and Greal North Run. They tume(J out in force 8t Several Kiltwalks and participated in the virtual ch8llenge '60milies in April,. In addilion. 5UPPOrters carried out many rnore fundraising events and actiwties. A truty touching initiatwe in 2024 was the prrxluction of a Tribute muial in Manchester to Andy Rourke, bassist of The Smiths who died of pancreatic cancer. The tribute to Andy joins wth the many tributes family members made to loved ones. Sincere thanks to every person who gNes Iheir passion, time and resources.
PANCREATIC CANCER ACTION CEO'S REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024 BUILDING FOR FUTURE SUCCESS Extensive efforts were undertaken throughout the year to build the basis for future success. You 111 see in these accounts that four new Trustees were apptsinted. ColledNety they bring a wealth of knowledge and wisdom in the field ol Business, Public Services, Marketing and Communicabons and Law lo drive Pancreatic Cancer Action forward. We welcome all our new trustees to Ihe PCA fami. whilsl thanking those who returned in 2024 for their dedicated service. To the trustees that resigned during 2024. we ihank you lor the incredible amount of time and commrtment you dedicated to the charity. I recognise the investment of time and resources to develop the assets needed to propel our organisation forward. Much creative work has enriched content and given greater lunclionality improvements to the PCA website. This website. the'shop window, of our organisation will be at the centre of PCA'S communications strategy. A review of 811 our services began in 2024 and will ¢(>nbnue apace in 2025. Ntrw and aspirational giowlh Stiategies are undèr dèvelopment in all areas". Awarenèss. Advocacy, Education, Res¥ar¢h, Support. I look forward to sharing, in due course, our new &year organisational slrategy wlh exciting plans to pul PCA on a growth pathway for the benefit of many more people pancrealjc cancef. and their lamilies. A Ththony CumttMng1 (Sèp S. 202S. 11 11*1)) Anthony Cummings Chlèl Ex•cutlvé Offie•r Date.. 05 Sep 2025
PANCREATIC CANCER ACTION TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) FOR THE YEAR ENDED 31 DECEMBER 2024 The Trustees present their annual report and financial statements for the year ended 310ecember 2024. The financi81 slalernents have been prep8red in 8rdan the accountsng poliryes set out in note 1 to the rinancial staternents and cornply with the charity'5 Articles of Assouation, the Cotnpanies Act 2006, the Charities and Trustee Investment Iseotlandl Act 2005, the Charities Accounts Iscouandl Regulatitsns 2006 las amended) and "Accounting and Reporting by Charities." Statement ol Recommended Practice applicable to charities preparing their accounts in accordance with the Finanaal Reporting Slandard applicable in the UK aTrJ Republic ol Ireland IFRS 1021 (effective l January 20191". ObJectlve8 and ocUv1t Our purpose Pancreatic Cancer Action works to save lives thfough promoling earfier diagnosis of panCatIC Canr. We do this through promoting greater awareness of the symptoms of Ihe disease. the funding and development of medical education81 programmes. SUPPOrting patients through improved informats'on about P8ncreatic cancer either on our website or in print and by lunding research. Our vl8lon Our vision is that everyone survNes pancreatic cancer. Our mls8lon Our mission is lo improve survival rates of pancreatic cancer by ensuiing rn0 people are diagnosed earfy and that everyone has a¢¢e$$ to effe¢b've talments, $upporl. infomiaiion and ¢ar&. ObJoctlv•$ The chanty's objectives are.. Aw#rgne8$ - in¢rease public awareness and knovlttdgtr of pancreatic C8n¢er and its symptoms lo a¢hieve earty dia9nosis Campalgn and lobby the govemment and key stakehoklers for change to advance the standard of heahhcare for individuals affected by pancreatic ncer Traln and pro¥e pTreering educational resources for our medical and heatthcare communrties Innovatlve resear¢h we lund il. we support il - lo improv& &arfy ¢Jiagnosis and tlevelop eff¢¢tNe tr¢abn&nl$ lo improv¢ pan¢r¥ali¢ ¢an¢¥r outcomes Offer Ihe provision of practi1 and efflolional support and information to 811 affected by pancreatic cancer Now - we are the action charity and action is needed more than ever belore1 The Trustees have paid due regard to guidance issued by the Charity Commission in ijety(Jing what a¢livilies the charity should undertake. The Trustees. actlvltles The Trustees meet regularty lo develop and support strategies to meet Ihe charitable objectives. The Trustees currenty have a range of skills and experience Ihat range from medrallxienlffic. legal. corporate governance, finance and PR. direct and indirect lived experience of panrJeatic cancer. Role of Yolunteers I PCA Aetion Ambassadors The Chanty receives the very welcome assistance of volunteers. who help support a range of projects to raise awareness of pancreats"c cancer, provide support, review lrterature and lundraise in their coMmunrts. The chanty seeks volunteer assistance via the website. social media and ty word of mouth. Public benefit statement The Trustees confirm that they have complied wth the duty in Section 4 of the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public benefft.
PANCREATIC CANCER ACTION TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024 Achlevem•nts and rfoan¢& Using some of our objectives as headings and soTh other key areas not covered above. we have sel wt below highlights of activity and work in 2024 in our on90ing mission to improve survival rates of pancreatic CAnr by ensuring mole people are diagnosed earty and that everyone has access to effective treatments, supp(Nl, information and care. l. Awar•n•ss . Increase publlc avAreness and knowledge of pancreatlc cancer and Its symptoms to achleve early dlagnosls Pancreatic Cancer Acb'on PTovide5 indNidua15. comrnunitie5 and organi5ations with resources lo help raise and improve symptorn awareness of the worfd'5 tOU9hest eancer. We do ihis through providing posters, leaflets, booklets, online resources, and activrties within communrties. In our mission to improve earty diagnosis and sav¥ lives, symptom awareness Is key to ensunng people contact their GP lor support wrth any concems as soon as possible. We continue lo provide quallty accredlted health Infom)atlon resources lor communities who do not have English as their first language. Our translated online and print health educatlon resources are available to those who have Pollsh, Ur(lu, Punjabl. Bengall, Arablc or Gularati as their first language. In 2024 we progressed distribution of our transla¢ed resources to mullttur8l cen¢res aGro5S the UK. A$ well as providing fretr educational resour¢e$ lo individuals and ¢ommunilie$, Pan¢r88li¢ Can¢er Adion proactively progresses Innovative ways to engage wlh vanous communities in different ways. particularly targeting 'hard-to-reach groups.. In August 2024 we hosted a ¢Jedicated "Awareness We•k" In the East End ol Glasgow, as part of our ongoing Aetlon on The Ground Project. Our incre(Jible staff and volunteers were actively present wrthin local community areas helwng open more conversabons with people about the importance of symptom awareness. to aid earty diagnosis. Over the course of 7 days, activities induded the distribution of information leaflets. quick guides on pancreati¢ canceff to discussions of symptoms wlh the public in shopping cenlres. loodb8nk$, communty cent$. ¢hur¢h&$. $port$ cenlres. Throughout August, w& raisod 8waren8ss in a varièty ol ways to ¢omplement the dedicated awarenes$ weèk a¢tivity. This includèd purple branded "Pancanvan" being posrtioned in prominenl areas high footfall, 25.000 phamacy bags featuring symptom information distributed by communty pharniaaes, S.000 Pancreatic Cancer Action branded cups distributed in local coffee shops, and symptom infomiation on washroom panels in 30 pubs. Alongside our public engagemenl ac¢ivilie5 we invested in digital advertising to broaden our messaging. providing strong focused engagement in an area with particularty low levels of 5ymplom 8w8reness and suryiv81. Arn8zing organic media 8¢tivity w8s also achieved including onlinè and digltal nèws Storiès, intewiews on local radio and Celtic TV. November's Pon¢reatl¢ Can¢r Aw#r¢n¢$$ Mrjnth - kn¢)wn acro our ¢ommunity a$ 'PCAM" provid99 8n opportunity to amplify the importance of symptom awareness and share key heath infomation wrth the public. Our innovative and groundbaking "MISSED" campaign in 2023 was Pancreatic Cancer Acth)ns biggest digital syrnptom awareness campaign. highlighbng those who had passed away from pancrealic cancer because their syrnptoms were rnissed. These symptoms were eilher missed by heatthcare prolessionals or by the individuals Ihernselves. Building on the suc5$ of that campaign. PCAM 2024 evolved lo "MISSED moments" When the syrnptoms of panueatic cancer are missed. everything Is Inis5ed." early diagnosis. life-5aving treatment and precious moments with ltsved tsnes. Our "MISSED moments" campaign enabled people to share the mtsments they missed wrth their loved ones and highlight the urgent need for awareness, education and earfy diagnosis. Following the success of our East End of Glasgow Awareness Week, we led another geographical specffic syrnptom awareness campaign in November 2024. focused on North East England, speclflcally Northumberfand and Tyne & Wear. Throughovl the monlh. aWanesS of Panat1¢ cancer was raised with information on 50,000 phamiacy bag5. 8.OCX) branded coffee cup5 and 48 washroom panels in pub $trOOms. Our new campaign 'MISSED moments, was ad¥erti5ed across the Tyne and Wear Metro, stories weie 5h8red through media ouuets, and inve5tsnent in targeted social media advetbsing to the general public and heajthcare professionals. An amazing group ofvolunteers also kn.ndty led an awareness stand at The metrontre.
PANCREATIC CANCER ACTION TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024 We continued to support collaborative campaigns. wlh Purple Lights UK and The Wortd Pancreatic Cancer Coalition. Supporters across the globe help arrange buildings and landrnarks to light up purple to shine a light on the disease and share symptorn information during November. parbcularly on World Pancreotic Cancer Day, which fosteis an inspirin9 communty spirrt to irnprove global survival. A priffle example of this is Pancreatic Cancer Actions, annual Pfesence at Glasgow C•ntrnl Station on Worfd Pancreatic Cancer Day. Arranged by one of our amazing supporters and Nets¥ork Rail. 2024's "Purple Takeoverf of Scotland's busiest train station was another huge success. Entertainment from The Glasgow Rock Choir and various musicians throughout the day attracted attention. with music bringing people together. We are very grateful lo our volunteers and team mernbers who helped share information with the public and collect generous donations. 2. Campalgn and lobby the govÈmmÈnt and kèy stsk•hold•rs lor ehanoè to advance thè standard of healthcare lor Indlvlduals affected by panereatlc eaneÈr. Wlth no significant improvement in pancreatic cancer survival rates in SO years, and a predicted increase in future incidence levels, we continue to urge government and key stakeholders to take urgent action. Our small but mighty team engage with MSPS. MPS and counallors to explain why action is necessary to irnprove patient experiences and pancreabc cancer survival rates. We continualty advocate for patients and families. building on years of campaigning to raise awareness of pancreatic Cancer and Ihtr urgtrnl netrd lo drive improvements in the &aty diagnosis tsf panc811¢ ¢an¢er, across the UK. Throughout 2024 we ¢onlinu¥d ¢0 WO in partnership vnth Canr 52, One Con1 Vol, The L$s Survlvabl Cancers Taskforce, The Scottish Cancer coalitn, the North Cancer Alliance (Scotlandl, and a number ol other coalitions of cancer chanlies. Partnership workin9 strengthens our colle¢tive voices to ensure patient and carers are at the heart of decision-making by politicians and govemment. Pancreatic Cancer Action continued to be key partner in the delivery of SCOT41P8'. The SHPBN Pathway Improvement Pr0cl for pancreatic and hepalocellular cancer. This wa5 delivered by the Scott18h Government and NHS Scouand. with support from cancer charities and partners such as ourselves. We have beèn a¢tivèty involved in drivin9 this important work to improve the timètram$ Ifom su$pi¢ion of ¢an¢or lo diagnosis and tre8lmènt, wrth a particular focus on patient and carèr èxpenènces. In November 2024 we provided briefings to all MSPS for the annual Panernatlc Cancèr Awar•n••8 Month d•bat• at Scottl8h Parllament, with a particular focus on the importance of SCOT-HPB and the positive resuhs from the pilot. However. we were deepty disappointed at the pilot project ending in 2024 wrth no continuty funding. We will continue to campaign for the leamings to be taken foThYard to improve patient and carer experiences and outcomes. We attended the 8nnu81 ScotU8h Cancer Conference in November which brings logelher in¢Jividu818, org8nisalion5. patients. pharm8ceutiGal companies. diniGian$. academics. poliw makers and ch8ri1ie$. Pancreatic Cancer Action had the privilege of hosting a breakout session ts.tled "Community Phamiacy - thè n•w Iront Ilne lor d•t•ctSng caneer èarly." The aim of the session was to emphasise the crucial role that phamacisls play in the earfy diagnosis of cancer. We chald a panel ol phamacists who spoke very passionately about Ihe need for direct referral lor community pharniaasls and the challenges they fa. Our Q&A session was very engaging. wlh discussions around pharmacy capacity. acces5 lo patient records and what more can be done lo educ8le communty phaGists about cancer. We also hosted an exhibition Stand providing 8 fantastic opportunity to share Panueatic CanceT Actions health infofrnation and resourcè$, in¢luding our accredrted educational resources for healthca professK)nals and patient infomiation booklets. Pancreatic Cancer Action contributed to the update of Thè Scottish Cancèr R•f•rral GuSd•lln•s and are pleased that our recommendations were taken forward lor the updates that a expected (o be published in 2025. We continue lo be an active partner campaigning for change in England and Wales. In 2024 this included contributing and supporting The National Pancreatic Cancer Audit. fesulb'ng in The National Cancer Audit Collaborating Centre INATCANI publishing a 'State of the Nation Report" in September 2024. on care received by people diagnosed wth pancreatic cancer in England 12020-20211 and Wales 120221. Pan¢at1¢ Cancer Action had recommended an audit of pancreatic cancer diagnosis and treatment for many years. Having fed into a feasibility study in 2022 and the development ol a scoping document in 2023 to identify priorities ol care, we are pleased to continue to be invofved in this vital work. We shall continue to campaign for the insights and recommendations frorn the audit and report to be irnplemented. as the catalyst for positive chan9e. reshaping of guidelines, improvements in early detection stregie5 and ulbmatety enhanGing the INes of those affeded by pancreatic cancer.
PANCREATIC CANCER ACTION TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024 In September 2024, Pancreats"c Cancer Acaion were delighted to support a gathering near Westmlnster, of the "purple family of community campaigners marking the 101h anniversary of the first Patliarnenlary Debate on pancreatic cancer. This was a resuh of a successfvl petition appeal by campaigner Maggie Watts, wh achieved over 100.000 signatures in 2014. lIe some progress is taking place. increased speed and action is urgently needed in our united mission to save lives. Pancreatic Cancer Action will continue to represent patients and c8r8rs, building on years of campaignin9 and collective adivity by ovr communty and together will continue to make a drfferèncè. Patient expenence and outcomes will be a key focus area for The UK governments development of a Natlonal Cancer Plan. to improve cancer prevention, diagnosis, treatment and aftercare. The commitment to the plan was announced in December 2024 and we will support the provision of evidence and contributs'ons on behalf ol patients. heatthcare professionals and the public. 3. Train and provide pioneering educational resources for our medical and healthcare communltie8. Pancreatic Cancer Action provides pioneering accredited e4eaming for GP8 and Pharrna¢lst8. Following the update lo our GP e-leaming hosted by Th? Royal Colleg? of General Pra¢lltloners IRCGPI in 2023, we launched a new improved eLeamin9 Module tailored for Community pharmacists and their team$ in 2024. Pharmacy staff have dalty InteraciSons wRh Ihelr customers, often buildln9 relalSonshlps that allow them to recognise subtle changes in hearth. This lamiliarty puls Ihem in a prime position to identfy the waming signs of pancreatic cancer and a welkinlomied pham)acisl can guide patsenls to seek urgent medical attention. By completing our comprehensive training module. phamiacy leams can gain crilical insight5 and equip themselves wrth the knowledge to.. Understand where the pan¢re8s 1$ and rt$ fvndions in Ihe IxJ¢ty Identify the risk laclors associated wrth pancrèatic cancèr and explorè its impact on peopl¥ Recognise the symptoms that may indicate panuealic cancer and require urgent ferra1 to a GP Build effective communicalion skills when speaking to customers showing symptoms or affected by pancreatic cancer. As universally accessible heamhcare professionals with gUlar Irusled contact wth their cuslomers, communty phamiary teams are uniquety positioned ¢0 spot eaty sign5 of pancreatic cancer and have the confidence lo lake 8¢tion that Could directty lead lo earlier (Jiagnoses and make 8 lrfes8ving differen¢&. Our nw Pharma¢y Team eLeaming module is ho$l&d by lh& pr&$tlgious Royal Phamat•ull¢al So¢l•ty IRPSI, Brltlsh Oncologleal Phamac•utSeal A•8oelation IBOPAI. The NHS L•amlng Hub and ELE Léarn, helping us ach and educate more phamiacists and phamiacy teams than ever befo. Upon successful completion of the module, partiapants receNe Continuing Professional Development ICPDI points and a certificate as a record ol their achievement. Pancreatic Cancer Action hosled an exhibition stand at The Pharmacy Show at NEC Birmingham in October 2024. Wth over 8.700 attendee5. It was the perfect opportunity lo promote our new and improved eLearning module for pharmacy teams, raisè awarenÈ5s of the uuual role ihey can play in the earfy diagnosis of p8ncr8ati¢ cancer and liaise with them face-t[aCe about thè drfference thèy can make to survival rates. We also promote our eLearning at Thè Scottish Canetr Conlèrnnc• in November 2024 and as noted earfier, hosted a breakout session tilled "Communty Phamiacy the new frontline for detecting cancer eady" Pancreatic CancerAction were proud to chair the active Q&A session which included discussions on current pilot programmes throughout the UK where pharmacists can directly refer patients onlo the cancer pathway. Our resource5 in educating pharmacy leams will be vrtal in aiding awareness and understanding of pancreatic cancer. Our focused awareness campaigns in the Easl End of Glasgow in August and NorthQast England in Novernber included a total of 75.000 pharmacy ba9s featuring panueatic Gqncer symptom inft>tmation. attracting the attention of both members of the public an¢J heatthcare teams. Alongsi¢Je our public awareness activrties, we invested in targeted advertising, engagemenl and outreach to Healthcare Professlonals In those geographical areas, helping maximise our impaci ol communty engagement.
PANCREATIC CANCER ACTION TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024 Throughout 2024 we continued to provide GP and Phamiacy packs across the UK. and we thank our cornmunty of volunteers who help disseminate inforniats'on on our resources in their local communities. We l¢)ok forward to our ongoing work with medical and healthcare communities to continualty drive forward irnprovements in awareness. eduration and eatlier diagnosis of pancte8tic cancer. 4. Innovatlve researeh lund It, we support It - to Improvè Èarty dlagnosls and develop effectlvè treatments to Improve pancreatlc cancer outcomes. Pancreatic Cancer Action has historic success providing pumppriming seed-funding lo kick-start innovative research projects and opportunities that have then progressed to larger inve5trnent from additional fvnders. As a sm811 charity we are not in a position lo invesl millions inlo research on the same scale as larger organisalions. however we are very proud to be driving Innovatlon Ihrough Smaller scale research project5 that èxplorè both data and science, lo bettèr undèrstand pancrèatic rAncer, earfier diagnosis and effective treatments. A fantastic example of thls 1$ our funding and ongoing partnership worting wth Dr Agnieszka Lemanska and thè research team at Th• Unlverslty ol Surrey. Pancreatic Cancer Action provided initial research funding to examine the link between diabetes and pancreatic cancef. The project was a retrospective case-conlrol study, examining a large sample of GP records of patients with diabetes. lo understand those who went on lo develop pancreatic cancer and those who did nol develop the disease. pIe v8riables could be exarnined including demographics. diagnostics, number of presenlalions lo primary care. and disease managernenl. The research findings contributed lo the development of a new findlng protocol for patients wth new onsèt diabetes and waight lo$$". ¥ new al9orilhm to identify patients la$tèr and speed up diagnosis. Wè hav¥ continued working wrth Thè Vnivèrsity of Surw and NHS England to ensure the project developed further and are delighted that additional partners and funding were established to enable a mulli-million-pound pilot, implementing the case finding protocol. lo be rolled out across England in 2025. We will continue to support this incredible developrnenl which involves activety idenlfying individuals who rnay have pancreatic cancer, especially those at higher risk and then lesting Ihem to confirm or rule out the presence of cancer. The seed-funding Panuealic Cancer Acb'on provided for the preliminary stages of this innovative research &n8bl&d fvrther research lo progr&ss al scale, lo &nabl& &v¢n bigg¥r Impa¢t in ouf united mi$$ion lo $8ve liv¥s. We Continue lo support the team al The Universty of Surrey a$ they explore further data inlerrogalion opportunrties to identrfy other factors and combinations ol variables that could help potential idents.fy at-risk patients earlier. We look forward to supporting more innovative research projects. and in 2024 our team progressed preparations lor a relaunch ol our Early Dlagnostlc Challenge Award scheme. This induded attending training and events with The Assoriation of Medical Research Charities IAMRCI. seeking 511PPOrt and legal advice. Alongside providing research funding. Pancreabc C8nc£r Action plays a vital role in supporting the wider rèsearch community and large re$earth projeds, by representing paiienl and carer voices. Ensuring lived experiences are considered at all stages Of research projecis is essential thmugh Patient and Publie Involvom•nt Ippii. 5. Offor the provlslon of prnctlcal and •motlonal support and Infom)atlon to all aff•ct•d by pancr•atle cancer. l of the health inforrnation Ihat Panat1¢ Cancer Action provides is certified and holds a UKiide "qualty mark as trusted heatth information. Highty trained medical professionals review the inlomiation. and it is independently assessed and acrJedited by the Patient Inforrnalion Foruffl. Pancreatic Cancer Action are proud to provide a range of acuedr(ed high-qualty Health Inforrnation Booklets that are easy tts understand and offers useful support ft)r Paiients. relatives and carers. Our b()Dklets have been created in a modular fomi, covering a wde range of topics to ensure users get the infomiatson and jviCe they need. Our booklets are now available in a dlgltal fom)at on our websrte, with pnnted booklets continuing to be available for ordering free of charge from our online shop and are available to both individuals and organisations, including hospitals and canr 5UPPOrt centres. Our innovalive Recipe 8ook 'Nourishing Your Body during Pan¢reatic Cancer Treatsnent" oontinue5 lo be extreThty popular. wilh unNue rerype5 and guKlance specifically foi those affected by pancreatic cancer.
PANCREATIC CANCER ACTION TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024 In 2024 we produced a new downloadable resource "The Role of Genetics in Pancreatic Cancerf, helping respond lo questions and concems from people. Our new guide covers everything people need to know about genes and genetic testing. 5UPPOrt available for those eli9ible for lesting. genetic conditions Ih8t increase the risk of pancreatic cancer and key signs and symptoms ts) watch out lor. We wll continually review how we offer support for patsents and families, to ensure there is a range of comprehensive quality inlomiation. Creating new worfd-dass accredited health inlomation is a lengthy process due to the need to involve and consurt medical professionals, peer rewewers. lay reviewers, patients and their families. health leaders and other charitable organisations. However, this process is necessary to SUre we can provide the best possible support lo the people who need us most. Pancreatic Cancer Action conts'nves to fvnd a dedicated Pancreatic C¥ncer Clinical Nurse Specialist within The Wesl of Scotland C8ncer Nefvrk. Based 8t Glasgow Royal Infirmary. the postholder provides Vrt81 additional resource to the speaalist team who colledivety support around 230 patients each year from across the Wesl of Scotlan¢J. Over 2,500 interactions with patients and their families take place every year, wrth In-person support at clinics, wards and appointments. as well as lelephone support. The post-holder also provides a vital role in weekly MuttFDisaplinary Team meetsngs. where heatthcare professionals follow a holistic approach to assessing and diagnosing patients. and Cating treatmenl plans to optirnise outcomes. Pancreatic Cancer ACtn Jre very grateftjl lo our te8m and volunteers vkno host awareness stsnds at hosPlt81s, providing an opportunity to tslk to patients and carers and shartr our 8UPPOrt information and re80urce8. Fundrnlslng In 2024, income was generated through a range of fvndralsing activitlès and donatlons, Includlng our amazing supporters taking part In d)allenge events such as Thè London Mafathon, The Great North Run and various KIlalkS. to name but a few. Pancreatic Cancer Action also hosted a new virtual event chalknge, 'fjO miles in April. that attracted people from across the UK to raise funds and awareness for pancreatic cancer. A variety of communlty and corporat• fundralslng acb'vilies also took place and we are continualty inspired by the passion, energy and enlhusiasm of supporters detennined to help Pancreatic Cancer Action in our mission of saving more lives through e8rty diagnosis. From coffee momings. bingo nights. charity dances. lo gdf day8, di$18neè ¢hallenge$ running. walkin9. swimming and climbing. we are incrÈdibty grateful lor thè dèdi¢alion of supporters arranging fundraising acti¥rties in Ihèir schools. workplacès and communities. THANKYOUI A huge thank you, also to our Incdible donors who support Pancreatic Cancer Action throughout the year and the kind generosity of l•gacl88 being bequeathed to our chanty and grant awards to support our actwrties. Pancreatic Cancer Action were honoured to Ihe chosen charity beneficiary for an innovative crowdlunding campaign in 2024 by The Smrths drummer Mike Joyce. to create a powerful mural In memory of beloved ba$s18t, Andy Rourk¢ who tragicalty passed away from pan¢reaii¢ ¢an¢er in 2023. Loc3led in ManGhester's Northein Quarter, on tho side of The Wheatsheaf Pub on Oak Streèt. the mural was launehed on World Pancre8tic Cancer Day 2024 as a fitting tribute to ROUt$ lrfe an¢J leyacy. This generated significant media attention including TV and radio and the mural continues to raise funds and awareness for pancreatic cancer. Trusts and grants We are very grateful to the many funders that give so genen)usty lowards our initiatives. activities and projects. In 2024 these induded £18.CKJO of restn'cted grants.
PANCREATIC CANCER ACTION TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024 Financial review The results for the year are summarised in the Statement of Finanaal Activrties on page 16. The Trustees are pleased to report that the charity's incoming resources for 2024 amounted to £633,97312023." £752,504), 12022.. £488,0891.12021'. £754.2171.12020.' £1.256.477,' an excepts'onal year which included a one-off transfer of £807.560 due to the merger wlh Pancreatic Cancer Scotland and £58.781 through the Coronavirus Job Retention Schemel12019'. £786.5051.12018.' £892.851 I. 12017.. £757.8121. The Trustees would like lo thank all those volunteers. fvndrai5ers and donors - corporate. tru5t5 and foundats'ons, s well as individual donors who h8v& supported the charity ovtrr the pasl years and upon whom we are dependent. Total spending on charitablè activrties was £492,318 12023." t465,4411, 12022". £450,195), 12021.. £513.8741, 12020.. £437,838112019". £609,931112018.' £669,1871.12017'. £669,077). The charity achieved a net deficit for the year o1-£222.41812023.' -£8,0771,12022'. £-241.7411,12021.' £-87.7401, 12020. £510,025112019.' £-115,305112018. £-24.634112017. £-169.31SI. Re8erygs pollcy 11 is the policy of the ¢harity Ihol unrestn'¢ted fvnd$ whi¢h have not been designated for 8 specffic use should be maintained to cover at least 6 months of operating expendrture. The Truslees consider that reseNes al this level will ensure Ihal, In the event ol a signfficant drop In funding. they will be able to continue the charity's current activities while consideration is gNen to ways in which addiknonal funds may be raised. At 31 st December 2024, the charrty held reseryes of £369,S1 01 which £103.440 was restricted. Free reserves stood al £193.256 which is in line vmh Ihe level of the reserves policy established by the board. structure, governnce and m•nag?ment The charity is a cornpany limited ty gvaranlee. incJJporated in June 2010. and is therefo govemed by rts Articles of A5soriation. Ils company registration number 15 07272699 and rts charity nurnbers a 1137689 IEngland and Wales) and SC049777 IS¢otlandl. The Trustees, who are also the ¢Jirectors for the purposè of company law, and who seNed durlng thè yaar and up to the date of signature of the financial statements were". H Matthews N Menezes N Mumford H Goodfellow L Condron R Legg C Carter E Cowan N Longworth L Nylander G Codaw Pi58nÈlli D Slater G Lesca T Matthews (Resigned 17 March 20241 (Resigned 18 March 20241 (Resigned 12 June 20241 (Resigned 15 Jufy 20241 (Appointed 18 March 20241 (Appointed 18 March 20241 (Appointed 18 March 20241 (Appointed 20Augusl 20241 None of the Tnjstees has any beneficial interest in the tharity. The members of the company guarantee to contribute £10 in the event of liquidation.
PANCREATIC CANCER ACTION TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024 The Trustees continue to keep the Charity's aclivilies under review. particularfy with regard to Y major physical or financial risks that may arise from time to tyme. and to monilor Ihe effectNeness of the system of internal controls 8nd other variable means. including insurance cover where 8ppropri8te. by which those risk5 already identtfied by the Trustees can be mrfjgated. Audltor In accordance wlh the company5 articles. a resolution proposing thalAlliotts LLP be reappointed as auditor of thè company will be put at The Annual Gen8ral Meeting. Dlselosur• of Infomiatlon to audltor Each of the Trustees has confirmed thal there is no Informal of which they are aware which 15 relevant to the audit, bLJt ol which the auditor is unawarè. They have lurther ¢onfimied that they have taken appropriate sltrps lo identify such relevant Inlormation and to establish that the audrtor is aware ol such infomation. The Trustees, port Was approved by the Board of Twstees. G Codaecl P18an•lll Chair of Tru8lee8 Dated.. 05 Sep 2025 10-
PANCREATIC CANCER ACTION STATEMENT OF TRUSTEES. RESPONSIBILITIES FOR THE YEAR ENDED 31 DECEMBER 2024 The Trustees, who are also the directors of Pancreatic Cancer Action for the purpose of company law. are responsible for preparing the Trustees, Report and the financial ststements in accordance with applKable law and United Kingdorn Accounting Standards (United Kingdom GeneraltyAccepled AOunty'n9 Pr8Cticel. Company law requires the Trustees to prepare finan(ial statements lor each finanaal year which gNe a true and fair view of the state of affairs ol the chanty and of the incoming resources and applicab.on of resour$, including the income and expenditu, ol the charilable company for that year. In preparing these financial statements. the Trustees are required lo.. select 5Ultable accounting policies and Ihen appty them consistenty.. observe th8 methods and principles in the Charities SORP., make judgements and esb'mates that are reasonable and pwdenl", state whether applicable UK Accounting Standar¢Js have been followed, subject to any material departures disclosed and explained in the financial statements". and prepare the financial slalements on the going concem basis unless r( is inappropriate to presun* that the charty 11 continue in operation. The Trustees are responsible for keepin9 adequate accounting records that disclose wrth reason8ble 8ccur8cy at 8ny time the financial position of the chanty and enable them to ensure that the financial statements compty with the Companies Act 2006, the Charities and Trustee Investment Iscotlandl Acl 2005 and the Charities Accounts Iscollandl Regulations 2006. They are also sponSible for safeguarding Ihe assets of the charity and hence for taking reasonable steps for the prevenlion and delection of fraud and other irregularities. 11
PANCREATIC CANCER ACTION INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES OF PANCREATIC CANCER ACTION Opinion We have audited the finanaal statements of Pancrealic Cancer Action (the 'charity'l for the year ended 31 December 2024 which comprise the statement of finanaal activrties. the balance sheet, the statement of cash flows and notes to the finanual slalements, including significant accounling policies. The finanaal reporting framework that has been applied in their preparation is applicable law and Unrted Kingdom Accounting Stsndards. induding Financial Reporting Standard 102 The Fin8nCI81 Reporting St8nd8rd applicable in the UK and Republic of Ireland Iunited Kingdom Generalty Accepted Accountin9 PraLtycel. In our opinion, the financial statements". give a true and fair view of the state of Ihe charilable companys affairs as al 31 December 2024 and of ils incoming resour¢es and application of resources, including rts income 8nd expendr(ure, for the year then ended", have been property prepared in acKordance wth United Kingdom Generally Accepted Accounting PraCts... and have been prepared in accordance th thè requirements of the Companies Act 20C6, the Charities and Trustee Investment Iscotlandl Act 2005 and regulalion 8 of the Charities Accounts (Scotlandl Regulations 2006. Ba81¥ for oplnlon We conducted our audrt in accordance wilh Internat*)nal Standards on Auditing IUKI IISAS IUKII and applicable law. Our responsibilities under those standards are lurther described in the Audilols Sponsibl11£1es for the audit ol the fin8nci81 stglemenls seclion ol ovr report. We a independenl ol Ihe charity in accordance wrth the ethical requirements that are relevant lo ovr audit of the financial statemenls in Ihe UK, including the FRC's Ethic81 Sland8rd, and we have fuifilleil our olher ethical responsibililies in accord4n wrth these requirernenls. We believe that the audit evidence we have oblained is sufficient and appropnate to provi¢Je a basis for our opinion. Conelu8lon8 r•latlng to golng eonc•m In auditing the financi81 statements. we have conduded that the Truslee8' use of the going ¢on¢em b88is of 8¢¢0unting in thé preparation of the financial $lalèments 1$ appropriato. Based on the work we have performed, we have not identffied any material uncertainties relating to events or conditions that. individually or collectivety. may cast significant doubl on the charity's ability to continue as a going concern for a period of at least fve months from when the finanrAal statements are auihorised for issue. Our responsibilitie$ 8nd the re$ponsibilili&s of the Trustees wlh SpecI lo going ¢on¢em are d88¢ribed in the relevonl se¢tion$ ol this roport. Other Inlomiatlon The other inforrn8lion ¢ompri5e6 Ihe inftsrm8tion induded in the annual report Olher Ih8n the n8181 st8tements 8nd our auditorf5 report thereon. The Trustees ale responsible foi the other information contained wrthin the 8nnu81 report. Our opinion on the financial statements does not cover the other infomation and, except to the extent otherwise explicit stated in our report, we do nol express any fom) of assurance conclusion thereon. Our responsibility is to read the other information and. in doing so. consider whether the other information is materially inconsistent wilh the financial slalements or our knedge obtsined in the course ol the audrt. or otherwise appears lo be malerialty mi5slaled. 11 we identify suth rnalerial inconsistencie5 or apparenl material rnisstatement5. we are required to determine whether this gives wise to a material misstatement in Ihe financial statement5 themselves. If, based on the work we have perfom)ed, we condude that Ihèrè is a material misstatement of this other infomation, we are required to report that fact. We have nothing to report in this regard. 12-
PANCREATIC CANCER ACTION INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE MEMBERS AND TRUSTEES OF PANCREATIC CANCER ACTION Opinions on other matters prescribed by the Companies Act 2006 In our opinion, based on the work undertaken in the course ol our audtt-. the inform8tion given in the Trustees. report for the financial year for which the financial statements are prepared. which includes the directors. reFK)rt prepared for the purposes of comp8ny law. is consistent wlh the rinancial statements," and the directors, report included within Ihe Truslees. report has been prepared in accordance wth applicable legal requirements. Mottgrty on whi¢h wg org required to rgport by ¢x¢eption In the light of the knowledge and understanding of the tharity and its environment obtained in the course of the audit, we have not identified material misststements in Ihe directors. report incjuded wrthin the Trustees. report. We have nothing lo report in respect of the following matters in relation to which the Companies Act 2006 and the Charities Accounts (Scotlandl Regulations 2006 require us to report to you rf. in ouf OpinTh. adequate and proper accounting records have not been kept. or relums adequate for our audit have not been received from branche5 not visrted by us., or the financial slalements a not in agreement wlh the accounbng records and retums., of ¢ert8in disclosures ol Iruslees, rernuneralion speoffied by law are not made.. or we have not 1Ved all the information and explanations we wuire for our audit.. or th& Trustees were not entrtled lo prepare the financial statements in ac¢ord8n¢e with the Small ¢omp8nie$ regime and take advantage ol the small companies. exemptions in preparing the Trustees, report and from the requirement to ppa a strategic pOrt. Re8pon8lbllltlos ol Truste As explained more lully in the statement of Trustees, responsibilities. the Tnjslees. who are also the dlreclors of the charity for the purpose of company law, are responsible for the preparation of the finanaal statements and lor being satisfied that they give a true and lair view. and for such intemal control as the Trustees detemine is necessary to enable Ihe preparation of financial ststements that are e from material mi5Sta¢ement. whether due to fraud or error. In pparIng Ihe finanri81 statements. Ihe Truslees are responsible for assessing the ch8rily's ability to continu& as a goin9 ¢on¢ern, di$¢losing. 8$ applicable, matters rela¢ed to goin9 ¢on¢ern and using the going concarn basis ol aceounlin9 unlèss the TfustèÈs erthfjr intènd to liquidat¥ th¢ ¢haritablè ¢omp8ny or to ¢8as8 oper8ts"ons, or hav• no rèalisbc aN•matNè but to do $0. Audltorfs responslbllllles lor the audlt of the financlal Statements We have been appoinl8d a5 audrtor under sedion 441111¢) of the Chavilies and Tru$lee Investment (s8nd) Act 2005 and under the Companies Ad 20[ an¢J in accordanc8 Wth the Acts and relevant règulations mad6 or having effect thereunder. Our objectives are to obtain reasonable assurance about whelher the financial statements as a Who are free from material misslatemenl. whether due to fraud or error. and to Issue an audito¢s report that includes our opinion. Reasonable assurance is a high level of assurance but is nol a guarantee Ihat an audit conducted in accordance with ISAS IUKI will 8Iw8ys deted a material rni55t8tefflent when il exist5. Misstslements arise frorn fi8ud 01 error and are considered material if. Individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of Ihese finanaal statements. Irregularities. including fraud. are instances ol non-compliance wilh laws and regulations. We design procedures in line with our responsibilities. oullined above. lo detect malerial misslalements in respect of irregularities. including fraud. The extent to which our procedure5 are capable of detecling irregulaiilies. induding fraud. is detsiled below. 13-
PANCREATIC CANCER ACTION INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE MEMBERS AND TRUSTEES OF PANCREATIC CANCER ACTION Extent to which the audit was considered capable of detecting irregularities, including fraud Our approach to identifying and assessing the risks of material misslaiement in respect of irregularitie5. including fr8ud and non-compliance with laws and regulation5. was a5 follows.. the engagement partner ensuied that the engagement tearn collectivety had the appropriate competents, capabilities and skills to idents.fy or recognise nori-compliance wrth applicAblÈ laws and regulations", we identified the laws and regulations applicable lo the company through discussions wth Trustees and other Management, and from our knovAedge and experience ol the sector,. we focused on specific laws and regulalions which we conSered may have a direct material effect on the financial staternents or the operabons of the charit8ble company. including the Comp8nies Act 2006. the Charities Act 2011. the Charities SORP. tsxalion legi51alion. dats protection. antbribery. employment. environmental and heaAh and safety legislation", we assessed the extent of compliance with the laws and regulations entified above through making enquiries of management and inspecting legal correspondence.. and • identified laws and regulations were communicated wilhin the audit team regularfy and the team remained alert to instance5 of nOn•cAp1lanCe throughout the audit. We 8ssessed the sus¢eptibilty of th& ¢haritable Company s finan¢ial slalemenls lo maierial misstatement, induding obtaining an und6rstanding ol how Iraud might o¢¢ur, by. making enquiries ol management as to whèrè they ¢on$ider¢d th$r¢ wa$ $u$¢¢ptlblllty to fraud, thelr knowledge ol actual, suspected and alleged fraud.. and • considering the intemal controls in place lo milale risks of fraud and non•CLJmpliance with laws and regulations. Audlt rn¥pon¥e to Identlff•d To address the risk of fraud through m8na9emenl bias and overridtr of ¢onlrols. we.. performed analytical procedures lo Ident ary unusual or unexpected relationships; reviewed all transactions listed". • assessed whether judgements and assumplions made in determining the attounting estimates were indicative of potenlial bias., and investigated the rationale behind Slgnffjnt or unusual Iran5aclions. In response lo the risk ol irregularil*s and non-¢omplwn¢e wilh law$ and ie9ulalion$, we designed pro¢¥dur$$ which included, but were not limited to." • agreeing financial statement disclosures to undertying supporling documentation,. and • enquiring of management as lo actual and potenbal lib"gab"on and daims. There are inherent limitations in our audrt procedures described above. The more Temoved that laws and regulations are from financial Iran58ctions. the less likety it is thal we would become aware of non-compliance. Auditing standards also limit thè audtt procedures requirèd to identify non-compliance wth laws 8nd iegulations to enquiry of the Trustees an¢J other managemènt and the inspection of regulatory and legal correspondence, rf any. Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealmenl OT colusion. A further descripb'on of our responsibilibes is available on the Finanryal Reports'ng Council's website al.. httys'.11 VW.[r.olg.uk18ud1t9rsre$pOsibIIrtIe$. Thi$ des(xiption forms part of our auditorfs report. 14-
PANCREATIC CANCER ACTION INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE MEMBERS AND TRUSTEES OF PANCREATIC CANCER ACTION Use of our report This report is made solely to the charrtable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charrtable company's trustees, as a body, in accordance with Regulation 10 of the Charities Accounts Iscollandl Regulations 20C6. Our audit work has been undertaken so that we might state to the charbtable cornpany's members and trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the lullest extent pemiitted by 18w. we do not accept or assume responsibility to anyone other than the charitsble wmpany. the Gharitable mpanY5 members as a body and the Gharilable company s trusteès as 8 body, for our audrt work, foi this rèwjrt, or foi thè opinions wè havè fomèd. S4.4.. A4..a,4L Stethn Meredith Isop 5. 2025. 327k¥Th} St•ph•n M•redlth BA FCA DChA Isènlor Statutory Audltorl for and on behalf of All10 LLP 05 Sep 2025 Chart•r*d A¢¢ountonts Statutory Audltor 3 London Square Cross Lanes Guildlord GU1 1UJ 15-
PANCREATIC CANCER ACTION STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31 DECEAIBER 2024 Unrestricted Restricted funds funds 2024 2024 Totsl Unrestricted Restricted funds funds 2023 2023 Total 2024 2023 Note8 Income from: Donations and legacies Other Ir8ding activities Investments 594,0 2.943 7.670 29,264 623,360 2.943 7.670 571.774 3.334 7.039 170,357 742,131 3.334 7,039 Total Income 604.709 29.264 633.973 582.147 170.357 752,504 Expenditure on.. Raising funds Charitsble adivilies 322.757 317,928 41.316 174,390 364.073 492,318 276.495 288,539 18.645 176,902 295,140 465,441 Totsl •xpèndltur• 640,685 215.7C6 856.391 565,034 195,547 760,581 Nèt •xpèndltuM 135,976} 1186,442} 1222,4181 17,113 125,1901 18,0771 Transfers befv4een funds 16,093) 6,093 Ne¢ movement In fundj 142,069} 1180.349) 1222.4181 17.113 125,1901 18,0771 R•eonelllatlon of lund•: Fund balanS al 1 January 2024 308.590 283.789 592.379 291.477 308.979 600.456 Fund balances at 31 D•e•mb•r 2024 266,521 103,440 389.961 308,590 283,789 592,379 Th# 8t8lemenl of financi81 adivities includes am gains and l¢Mes recognised in Ihe year. All income and expenditure derive from continuing activities. 16-
PANCREATIC CANCER ACTION BALANCE SHEET AS AT 31 DECEMBER 2024 2024 2023 Notès Fixed assets Intangible assets T8ngible assets 12 13 46,012 27.253 73.265 Current a88ets Stocks Debtors falling due after one year Debtors falling due within one year Cash 81 b8nk 8nd in hand 14 15 15 4.565 3.675 333 78.865 545.716 54.375 331.620 39J.560 628.589 Credltor8'. amounts falllng du• thIn on? year 18 193.8641 136.2101 N•1 ¢urr¢nt o8$¥ts 296,696 592,379 Totsl a$$•t• l*$$ ¢urrent 11obllbtl•• 369.961 592,379 Th• lund$ ol th• ¢harlty Restricted income funds Unrèstrictèd funds 18 103.440 2e6.521 283,789 308,590 369,961 592,379 05 Sep 2025 The fin8nci818ts1em&nl$ were ¥pprov¢d by the Tru$lee$ on ......................... ulio cM2eo-Fis2nelli (Sep 5. 2025. 2.-32wnl G Codacci Pisanelli Chalr of Trustees Company registration number 07272699 IEngland and Wales) 17-
PANCREATIC CANCER ACTION STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2024 2024 2023 Not•s Cash flows from operatlng acvIlle9 Cash 8bsoibed by opeiatsons 21 (142.026} 146,0521 Investlng actlvltles Purch8se of intangible assets Purchase of tangible fixed assets Inveslrnenl income re¢eived 147.140) 132.6001 7.670 7.039 N•1 eash lu8•d Inllg•n•ratèd from Invèstlng aetlvltl•$ 172.070) 7,039 Net cash generated from flnanclng act1v1 Net decrease In cash and cash equlvahnts 1214.096 139,0131 Cash and cash equivalents at beginning of year 545.716 584.729 Cash and ¢a$h oqulv•l•nts •t •nd of y•ar 331,620 545,716 18-
PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 Accounting policies Charity inforrnation Pancreatic Cancer Action Is a registered charity an¢J a company Incorporated by guarantee with no share capital, exernpted under section S of the Companies Act 2CK)6 from the requirement to use"Limited' as part of its name. It is incorporated in England and Wales under registration number 07272699 and ts registered office 1$ 3 London Square. Cr05s Lanes. Guildford. England. GU1 1 UJ. Correspondence address is Suite 3.10 Covautt, Fullarton Road, Cambuslang. Glasgow, G32 8YL. 1.1 Aeeountlng conv•ntlon The fin8ncial statements have been prepared in 8ccordan¢e the charity'5 Ststement of RecommerKled Practi applirable to charities prèparing accounts wrth the Finanual Rèporting Standard applicable in the UK and Republic of Ireland IFRS 1021, the Companies Act 2(X)6, the Charities and Trustee Investment (Scotlandl Act 2005, the Charities Accounts (Scotlandl Regulations 2006 las amended), FRS 102 "The Financial Reporting Standard applicable in Ihe UK and Republic ol Ireland. I"FRS 102.1 and the Charities SORP "Accounting and Reporting by Charities.. Slalement of Recommended Practice applicable to charities preparing their accounts in acc4rdance with the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021" (effective 1 January 20191. The charty is a Public Benefit Entity as defined by FRS 102. The financial statements are prepared in sterfing. which is the functlonal Currenq of the charity. Monetsry amounts in these financial statements are rounded lo the nearest £. The financial statements have been Prepared under the historical cost convention. The principal accounting policies adopted are set out below. 1.2 Golng ¢on¢•m At the lirne of approving the financial statemenls. Ihe Trustees have a reasonable expectation that the charity has adequate sourceS lo continue in operational exislence for the foreseeable future. Thus (he Trustees continue lo adopt the going concem basis of accounling in preparing the finanaal staternents. 1.3 Charttable funds Unrestricted funds are available lor us& at the discreb.on of the Truste&s In furtherance of th6Ir charrtable oblecbves. Restricted funds a subjed 19 speGifiG condrtions by donors or grantors a$ lo how they may be used. The purposes and uses of the restricled lunds arè set out in the notes to the finanaal stat6ments. IA Income Income is recognised when the charity is legalty entitled to it after any perfomiance conditions have been rnel. the amounts can be rneasured llabty. and it is probable thal income wll be received. Cash donations are recognised on receipt. Olher donab.ons are CogniSed once the charty has been notified of the donation. unless perfomance conditions require deferral of the amount. Income tax recoverable in relation to donations recewed under GrfiAid or deeds ol covenant is recognised at the lirne of the donation. Legacies are recognised on receipt or OtheSe rf the charty has been notified of an impending distribution, the amount is known, and receipt is expecte(l. If the amount is not known. the legacy is treated as a contingent asset. Gifts of assets and seNices are recognised at market value to the charity. 19-
PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024 A¢coun¢ing policies (Continuedl 1.5 Expendlture Expenditure is rewgnised once there is a legal or construdive obligation to transfer eoonornic benefit lo a third party, it 15 probabl8 that a transfer of ewnomiG benefits will be required in settlernent, and the arnount of the obligation can be measured reliably. Expenditu is classified ty aclivty. The costs of each aclwity a made up of the total of dIrt costs and shad costs. induding support costs invofved in undertaking each activity. Direct costs attributable to a single activity 8re allocated directy to that activty. Sh8red c05t5 whth contsibute lo rnore than one activity 8nd support Costs which arè ntst attributable to a single activty are apptsrtioned between those activrt*s on a basis consistent with the use ol resources. Central staff costs are allo¢aled on the basis of lime spent, and depreciation charges are allocated on the portion of the assèfs use. Expenditure hos be&n allo¢aled between the main headings in lh& Stslem&nl of Finana81 A¢tivilie$ on the basls of tho type ol a¢tfvNy to which they relat¢. indudln9 irrècoverable VA.T. Income and expenses have not been netted off. 1.6 Intanglbl• flxed a88ets other than goodwlll Int8ngible assets acquired separalety from a businèss are recognised at ¢o$l and ar& subsequ8nty measured at cost less accumulated amort1saln and accumulated impaimient losses. Intangible assets acquired on inlemalty generated assels a CogniSed al the acqui5rtion dale where it is probable Ihat the expec¢ed fvlure economic benefits Ihat are attributable to the asset will flow ¢0 the entity and the fair value of the asset can be rneasured reliabty.. the intangible 88$trt 8ri8es from ¢onlradual or other legal ghls, and the intan9ible asset is separablè from thè ènity. Amortisation is re¢ognised so as lo voile off Ihe cost or valuation of 8$sets $$ ¢h#ir resKJual values ovèr their useful lives on the lollowin9 bases.. Soare Website Development Costs 33.3% on cost 14.3% on cost 1.7 T4n9lbl¢ fixed ¥•¥ets Tangible fixed assets are initialty rneasud at cost and subsequentty meaSUd at cost or valuation. net of depwation and any impairmenl losses. Depreaation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases.. Fixtures, fittings & equipment Computers Motor vehicles 25% on cost 25% on cost 25% on cost The gain or loss arising on the disposal of an asset is detemined as the dIffenCe between the sale proceeds and the carrying value of the asset. and is recognised in the statement of finanual aciivibes. 1.8 Impaim•nt of fix ass•ts At each reporting end date. the charity reviews the carying amounts of rts tangible and intsngible assets to determine whether there is any indication that Ihose assets have suffered an impairrnent loss. If any such indication exists, the recoverable arTK)unt of th8 asset is esb"wnated in order to determine the extent of the impairment loss lif any). -20-
PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024 A¢coun¢ing policies (Continuedl 1.9 Stocks Stocks are stated at the lower of c95t and estsrnated selling price less Costs to Gomplete and Sell, Cost Colllprises diiect materials and, vthere applicable. direct labouT costs and those overheads that have been incurred In bnnging the stocks to their present locatson and condition. Items held for distribution at no or nominal consideratn are measurefl the lower of placement cost and cost. The charity are recognising 80% of the stock as free slock issues to support activities raising fvnds and awareness. The balance recognised on Ihe b818nce sheet 15 the residu81 value of the stod(. Nel realisable value is the estimated seHing price less all estimated costs of cornpletion and costs to be incurred in marketing. selling and dislribution. 1.10 Cash and cosh equlv¥lents Cash and cash equivalents include cash in hand. deposits held al call with banks, other short-term liquid investments wrth original maturities of three monlhs or less. and bank overdrafts. Bank overdrafts are shown wrthin borrowings in cvrTent liabilrties. 1.11 Flnanelal In8trum•nts The charity has elected to appty the provisions of Section 11 'Basic Financial Instruments, and Section 12 'Other Financial Instruments Issues. of FRS 102 to all of its finanrA81 instruments. Flnanci81 instrument$ ar¥ re¢ogni$&d in the ¢hanty'$ balance sh¢t when lh ¢hathy b&¢omes patty lo th¥ ¢ontractual provisions ol the instrument. Financial assets and liabilitS a offset. wilh the net amounts pSented in the financial statements, when there is a legally enIoratsIe right to sel off the recognised amounts and there is an intention to settle on a net basis or to reali5e Ihe asset and seltje Ihe liability simullaneousty. B•$i¢ financio185sets Basic finanaal assets. whth indvde deblors and cash and bank balancEs. are inilially measured at transaclion price induding transaction costs and are subsequentty carried al amorts'sed c05t Using the effective interest melhod unless the arran9emenl con5tilules a financin9 tr8nsaclion. where the Ir8n$8clion is me85ured 81 the present value ol the lulvre receipt5 discounted al a market rale of interest. Finan31 8ssel8 cl8ssiffied as receivable wrthin one year are not amortised. Baslc flnanclal Ilabllltl•s Basic financial li8bilities. in¢luding ¢redrtors and bank loans are Tnits'alty re¢ognised al Iran$a¢tion prits unless the arrangement constrtutes a financjng transaction. vthere the debt Instrument is measured at the present value of the future payments discounted at a market rate of Interest. Finanual liabilrts classified as payable wrthin one year are not amortised. Debt instruments are subsequentty carried at amortised 31. using the effective interest rate method. Tr8de creditors are obligations to pay for goods or seTrices that have been 8cquired in the ordinary eouise of operations from suppliers. Amounts payable ale dasstfied as current liabilities rf payrnent is due within one year or less. If not. they are presente¢J as non-current liabilib"es. Trade creditors are recognised inth'ally at transaction price and subsequentty measured at amortised cost using the effectwe interest method. Derecognition of financial liabilities Financial liabilities a derecognised when Ihe charity's contractual obligations expire or are discharged or cancelled. 21
PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024 A¢coun¢ing policies (Continuedl 1.12 Employee beneffts The cost of any unused holiday entNlement is recognised in the period in vthich the employee'5 servws are received. Termination beneffts are recognised immediatety as an expense when the charity is demonstrably committed to terminate the employment of an employee or lo provide lemiinalion benefits. 1.13 Retirem•n¢ benofits Payments to defined contribUtn retirement benefft schemes are charged as an expense as they fall due. crttlcal accoUnng e5mateS and judgements In the application of ¢he charity's arxounling poliries. the Trustees are required to rnake judgement5. estimates and assumptions about the carrying amount of assets and liabilth'es Ih818re not readily apparent from olh8r sources. Thè èstimatès and associated assumptions arè based on historical eKp¥rf¢n¢e and oth&r factors that are considered to be relevant. Actual resuhs may differ from Ihese ests"mates. The estimates and underlying assumptKJns are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised Whe the revision affects cnly that period, or in the period of the revision and fulure penods where the ievision affects both current and lulure periods. Kèy 8oure•8 of ••tlmatlon une•rtalnty F81r v8lu¢ of Glfts In Klnd The Iruslees have exercjsed judgement in recognising and valuing grfts in kind, induding donated goods and services. Recognition is made when enlrtlement 15 eslablished. receipl is probable, and value can be reliably measured. Falr value Is baseil on estimaled market prices or equlvalent services rat&s at the date of donatlon. Donatlons and legacles Unrestrfcled Restrlcted funds funds Total Unrestrtcted Restrlcted funds funds Total 2024 2024 2024 2023 2023 2023 Donations and grfts Legacies receivable Grants receivable for core activities 581,248 12.848 11,264 592,512 12.848 544,215 22.559 14,539 98.558 558,754 121.117 18.IM)O 18.0 57,260 62.260 594.096 29.264 623.360 571.774 170.357 742.131
PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024 Other trading activities Unrestricted Unrejtricted funds funds 2024 2023 Sales of merchandise 2,943 Ineomè from Inv••tm•nt• Unmtrfct•d Unrestrlcted fund• fund¥ 2024 2023 Interest receivable 7,670 7,039 Exp•ndltur• on ral$lng lund8 Unr•strlcted R•slrlctsd fund$ fund$ 2024 2024 Total Unrnstrtcted Re8trlcted fund8 fund8 2023 2023 Total 2024 2023 Fundralslng and publlclty Fundraising costs Staff costs Depreciation and impairment Support costs 126,436 159.204 126,436 1%.905 91.592 152.271 91,592 168,205 37,701 15,934 137 26.603 137 29,314 21,296 3,61S 24,911 2,711 307,600 41,316 348,916 270.603 18,645 289,248 Tradlng costs othe¥ trading actiwties 15,157 15,157 5,893 5,893 Total costs 322,757 41.316 364.073 276,495 18,645 295,140 -23-
PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024 Charitable activities Raising Supporting Medical aw#r•nèss rèsearth Ucation Patient 5UPPOrtI Information 2024 Total 2024 Total 2023 2024 2024 2024 Staff costs Depreciation and impairment Other costs 167.421 18.133 36,700 32.435 254,689 254,142 5.592 124.494 45 12.386 93 29.387 81 22.151 5,811 188.421 227 162.195 297.507 30,564 66,180 54,670 448,921 416,564 sha of sUPPOrt costs (see note 91 Share ol governance costs16ee note 91 21.264 2,303 4,661 4,124 32,352 40,351 7.262 787 1.592 1.407 11.048 8.526 326.033 33.654 72.433 60,198 492,318 465,441 Analy$l¥ by fvnd Unrestricted funds Re$lri¢t¥d fvnds 229.859 96.174 13.818 19.836 44.878 27,555 29,373 30,825 317,928 174,390 288,539 176,902 326,033 33,654 72,433 60,198 492,318 465,441 -24-
PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024 Charitable activiti (Continuedl For the year ended 31 December 2023 Ralslng Supportlng ¥wane$S reSeah Medlcal education Patlent supportl Infonnatlon Total 2023 Staff costs Depreciation and impaimient Other costs 158.002 143 100.840 17.798 16 35.354 32 42.988 36 27,434 254.142 227 162,195 258,985 29,174 57,950 70,458 416,564 sha of sUPPOrt ¢osls18ee nole 91 Share ol governance costs (see note 91 25.084 5.301 2.826 597 5.613 1.188 6.828 1.442 40,351 8,526 289.370 32.597 64.749 78.725 465,441 AnalyBl• by fund Unrestricted funds Restricted funds 205.911 83.459 14.364 18,233 37.191 27.558 31,073 47,652 288,539 176,902 289,370 32,597 64.749 76,725 465,441 Tru¥tee None ol the Twslee$ lor any persons Connected with them) i¢¢*ived ¥ny mneratIOn during the yew and none ol them were ieimbursed traveuing exp&ns&s1202& ÉNill. -25-
PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024 Support costs Support Govemance costs costs 2024 Support Governance costs costs 2023 Rent Office costs Telephone costs Computer c05tS Insurance Stsff welfarè Training, recruitment and internship costs 8ook-keeping and Accountan Bank Chargès 18,970 3.724 2.857 18.692 3.327 1,909 18,970 3.724 2,857 18.692 3.327 22.268 2.841 3,140 24.718 3,029 22,268 2.841 3,140 24.718 3,029 4.501 4.501 5.196 5.196 3.082 199 3.082 2.885 474 2,885 474 Audlt fees Audit fees prior year underlloverl accrual Legal and professional 11,650 11,850 11,100 11,100 2.850 5.056 2.850 5,056 17001 3,240 17001 3,240 57.261 19.556 76,817 64.551 13.640 78,191 Analysed between Fundraising Charitable a¢¢N'e5 24.912 32.349 8.508 11.048 33,420 43,397 24.200 40.351 5.114 8,526 29,314 48,877 57,261 19,556 76,817 64,551 13,640 76,191 Governance cos¢3 indude payments of £8.75012023 - £8.5001 for audit fees and £2,WO12023.' £2.6001 for ¥¢¢ouni$ preparation fees. 10 Employ••8 The average monthty number of employees during the year was-. 2024 Number 2023 Number 13 13 Employment costs 2024 2023 Wages and salaries Social security costs Other pension costs 406,678 34,851 lo,(5 380,476 32,403 9.468 451.594 422.347 -26-
PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024 10 Employees (Continuedl There were no employees whose annual remunerat•Jn was more than £80.000. Remuneratlon of key management personnel The iemuneratson of key management personnel is as folltrws. 2024 2023 Aggregate compensation 52,429 53,231 The key management personnel ofthe Charity is Conside to be Ihe CEO. 11 Taxatlon The company is a registered charity and is. therefore. exempt from taxalion on ils charitable acts'vrties. 12 Intonglblo fix•d o8$ts Softar• Wobilt• D•v•bopmant Totsl Ct At 1 January 2024 Additions- intern81ty developed 12.140 35.000 47,140 Al 31 De¢ember 2024 12.140 35,000 47,140 Amortl•atlon and Impalm$nt At 1 January 2024 Amortjsation tharged for the year 1.128 1,128 At 31 December 2024 1.128 1,128 Carrylng amount At 31 December 2024 11,012 35,000 46,012 At 31 December 2023 -27-
PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024 13 Tangible fixed assets Flxtures. Cofflputer fitbngs & equiprrnt Alotor vehicles Total Cost At 1 January 2024 Additions Dl$posal$ 10.612 12,600 17,1801 12.245 22.857 32,600 112,6661 20,000 15,4861 At 31 Daeèmber 2024 16,032 6,759 20,000 42,791 D•pr•elatlon and Impalrni•nt At 1 J8nu8ry 2024 Depreciation charged in the year Eliminated in respect ol disposals 10.612 347 17,1801 12,245 22,857 5,347 112,6661 5,000 15,4861 Al 31 December 2024 3.779 6,759 5,000 15,538 Carrylng amount Al 31 December 2024 12.253 15.000 27,253 Al 31 December 2023 14 Stock$ 2024 2023 Flnished goods and goods for resal8 4,56S 3,675 15 D•btor• 2024 2023 Amounts falllng du• wbthln on• yèar: Prepayments and accrued income 54,375 78,86S 2024 2023 Amounts falllng due after more than one year. Prepayments and seeu ineomè 333 Total debtow¥ 54.375 79.198 -28-
PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024 16 Creditors.. amounts falling due within one year 2024 2023 other tsx8tion 8nd so(i81 serIty Trade creditors othèr credrtors Accruals and deferred income 12.171 36.322 19,265 28.106 10.010 7,916 18.284 93.864 36,210 17 Retlrement benefit •cherne8 2024 2023 Dellned conlrfbutlon •cheme¥ Charg& lo the s1olmenl of Flnandal A¢tiviti$s In r$p¢d of d¢fin¢d contrlbutlon schome$ 10,065 9,468 The ¢h8rity operates a defined ¢onlribybon pension $¢heme for all qualifying employe&$. Tho a$$$ts of th& $¢heme are held separatéty from those ol thè charity in an independentty administered fund. 18 R•8trfet•d lund8 The restricted funds of the charty comprise the vnexpended balances of donations and grants held on trust subject to 5pecAfic condition5 by donors as to how Ihey may be used. At 1 J•nuory 2024 In¢omlng re8ourtÈ8 Rè8our¢è8 èxp#nd•d Tr•n$f•rn A131 Dèeèmbtr 2024 Pat & Paul Powapp Recipe Book PC Aware Carnpaign HCP Education Patient Information Booklets NIPanC Tianslation of iesourc&$ Research Pancreatic Cancer Scotland PC Aware North East England Action on the Ground Glasgow Project Communty volunteers 21,189 17.200 10,645 11,264 110.4461 22,007 17.200 6,432 500 {4,2131 15.0001 {4,320 {6.2731 5.500 3.500 820 5.273 5.000 5,845 5,845 493 22.500 175,197 20.000 14931 13.5001 {150,7411 120.1)001 22.000 24,456 9,760 {9.7601 1960} 283,789 29.264 {215,706} 6,093 103,440 -29-
PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024 18 Restricted funds (Continuedl Prevlous year: At 1 January 2023 Incomlng resources Resources expended Trnnsfers At31 December 2023 Pat & Paul Powapp Recipe Book Patient Inforniation Booklèts NIPanC Translation of resources Rese8rth Pancreatic Cancer Scotland PC Aware North East England Action on the Ground Glasgow Project Community volunteers GP Packs 12,60S 17,200 14.335 8,357 5.845 8.584 21,189 17,200 10,645 1.000 7,955 14.6901 116,3121 5.845 493 22.500 175,197 20,000 {1.5071 22.500 98.558 20.000 247.677 1171.0381 9.760 9.760 960 {2.0001 308,979 170.357 1195,5471 283,789 Restricted funds relate 10 9ranls received for lh& spefyfi¢ pu1$•$ a$ $¢1 oul above. Any amount unsponl 1$ camed forward to be spent In the next financial year. A transfer of £6.093 betren unrestricted and restricted funds has been made in the year ended 31 December 2024. 19 Analy¥ls of net assets between fund$ Unrnstrtcted fund$ 2024 Re8trtcted funds 2024 Totsl 2024 At 31 December 2024: Intangible fixed assets Tangible 8sset5 Current assetsllliabilitiesl 46,012 27.253 193.258 46,012 27.253 296,696 103,440 2e6.521 103,440 369.961
PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024 19 Analy¥i¥ of net assets betwegn funds (Continuedl Unrestrlcted funds 2023 Restrlcted fund$ 2023 Total 2023 At 31 December 2023: Current assetsllliabilitiesl 308.590 283.789 592,379 308,590 283.789 592,379 20 Flnanclal commitments, guarantse8 and contlngent Ilabilitl To d8le, the charity h8s received £48,235 12023". £46.8971 in don3.0n6 from 501icitors rel81ing to old rnonies held in client ac¢ounts which they have not been able lo felum. The is a possibility that in thè futurg the clients in question could still retum lor these monies and. as such. the chanty has agreed lo refund part of the donation if this occurs. No provision has been ma¢Je in these finanual statemenls for any possible tEfund as the likelihood is remote and cannot be quantffied. The tharity ha8 committed lo sponsor a nursing post wlhin NHS Greater Glasgow & Clyde IGGCI for a three year period which siart&d in January 2023. The lotsl ¢ommilmenl over the n&xt 13 months 1$ expected lo be £46,87412023. £90,238). 21 Cash absorb by 0ratIOnS 2024 2023 Defiejt for the year 1222,4181 18,0771 Adlu8tm•nts for.. Investmenl income rewnised in stslemenl of finantyal a¢tiwties DeprecAation and impairment of langible fixed assets 17,6701 6.475 17,0391 364 Movements In worklng capltal.. Ilncreaselldecrease in stocks Decreasellincre8sel in debtor5 Increaselldecreasel in creditors 18901 24.823 57,654 200 14.5901 126,9101 Cash absorbed by operatlons 1142.0261 146,0521 22 Analysls ol changes In net funds The charty had no material debt during the year. 31